Published on 25/11/2022 12:14:19 PM | Source: ICICI Direct Ltd

Reduce Lupin Ltd For Target Rs.680- ICICI Direct

Posted in Broking Firm Views - Long Term Report| #Lupin Ltd #Pharma Sector #Broking Firm Views Report #Quarterly Result #ICICI Direct

Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel 

Download Telegram App before Joining the Channel

US better than expected; margin recovery critical…

About the stock: Lupin is a multinational pharma company engaged in manufacturing & marketing branded & generic formulations, APIs, biotech products as well as OTC medicines across multiple dosage forms & therapeutic categories.

* It is the third largest generic player (by prescriptions) in the US (market leader: 44 products; Top three: 113 products) along with being sixth largest company in the Indian pharmaceutical market

* The company continues to face headwinds especially on the US generics front due to plant compliance issues besides persistent price erosion in OSD

Q2FY23 Results: Revenues were in line with estimates with beat on US front.

* Revenues de-grew 1.3% YoY to | 4146 crore

* EBITDA margins declined 330 bps YoY to 10.5%

* Adjusted PAT came in at | 118 crore

What should investors do? Lupin’s share price de-grew 0.86x in past three years

* We maintain REDUCE rating due to 1) Sensitivity of margins recovery on few US launches, 2) Ongoing cost rationalisation, which is yet to bring sustainable cost reduction, 3) weak return ratios

Target Price and Valuation: Valued Lupin at | 680 i.e. 26x FY24E EPS of | 26.2.

Key triggers for future price performance:

* US- Resolving regulatory challenges and speeding up approvals and key launches (FY23: Spiriva and Darunavir) besides traction from recently acquired inhalation brands- Brovana® and Xopenex HFA®

* Lupin plans to strengthen the biosimilars portfolio, especially in EU and the US. Change in mix towards complex products and with expense optimisation to improve margin profile

* R&D investment earmarked now to evolve generic portfolio focused towards complex generics in injectable, inhalation along with biosimilars

* Exploring both organic and inorganic opportunities in different therapies for domestic formulations

Alternate Stock Idea: Apart from Lupin, in our healthcare coverage we like Cipla.

* Cipla has a long-drawn strategy of targeting four verticals viz. One-India, South Africa & EMs, US generics & specialty and lung leadership

* BUY with a target price of | 1350 


To Read Complete Report & Disclaimer Click Here


Views express by all participants are for information & academic purpose only. Kindly read disclaimer before referring below views. Click Here For Disclaimer